Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference

Plans to Initiate First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19, in February 2022 Completes Enrollment for RSVP, a Phase 2 Study of EDP-938 in Community-Acquired Respiratory Syncytial Virus (RSV) Infection in an Adult Population; Plans to Report Topline Data in the Second Quarter

Related Keywords

,Jennifer Viera ,Exchange Commission ,Enanta Pharmaceuticals Inc ,Enanta Pharmaceuticals ,Mass Enanta Pharmaceuticals Inc ,Nasdaq ,Initiate First In Human Study ,Inhibitor Specifically Designed ,Community Acquired Respiratory Syncytial Virus ,Adult Population ,Report Topline Data ,Second Quarter ,Protein Inhibitor ,With Plans ,Second Half ,Chief Executive Officer ,Healthcare Conference ,Fast Track Designation ,Asthma ,Biotechnology ,Disease ,Drug Discovery ,Infection ,Medical Specialties ,Pdf ,Virology ,3c Like Protease ,Antiviral Drugs ,Atypical Pneumonias ,Coronavirus ,Human Metapneumovirus ,Respiratory Syncytial Virus ,Rsv ,Sarbecovirus ,Severe Acute Respiratory Syndrome Coronavirus 2 ,Viruses ,